Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
Himanta Biswa Sarma took the oath as Chief Minister for a second consecutive term on…
The Securities and Exchange Board of India (SEBI) has proposed the major reform for the…
Dr. Ashok Kumar Panda has officially taken the charge as the Chairman & Managing Director…
Choosing the right fuel type is one of the most important decisions while buying a…
Himanta Biswa Sarma is one of the most influential political leaders in Northeast India and…
The Mental Health Awareness Week 2026 is being observed from 11 May to 17 May…